Please login to the form below

Not currently logged in
Email:
Password:

Dementia Discovery Fund

This page shows the latest Dementia Discovery Fund news and features for those working in and with pharma, biotech and healthcare.

Pfizer drops neuroscience R&D, cutting 300 jobs

Pfizer drops neuroscience R&D, cutting 300 jobs

It will also set up a dedicated venture capital fund to invest in other companies carrying out neuroscience R&D and “support continued efforts to advance the field”. ... Pfizer is already one of the founder members of the cross-company Dementia

Latest news

  • Woodford investment pushes Dementia Discovery Fund to £100m Woodford investment pushes Dementia Discovery Fund to £100m

    Woodford investment pushes Dementia Discovery Fund to £100m. Fund aims to back 40 projects over its 15-year term. ... Thanks to a £15m pledge from Neil Woodford's investment group, the public-private Dementia Discovery Fund (DDF) has now raised close

  • GSK and J&J back new UK dementia discovery fund GSK and J&J back new UK dementia discovery fund

    GSK and J&J back new UK dementia discovery fund. Pharma giants collaborate with government to find new treatments. ... GlaxoSmithKline, Johnson &Johnson and Pfizer have signed up to support a new UK government dementia discovery fund.

  • Freeman: More pharma-charity research partnerships needed Freeman: More pharma-charity research partnerships needed

    Similar partnerships have been launched in recent years for conditions, including dementia and Parkinson's disease - both areas of significant unmet medical need. ... Earlier this year, Lilly, Pfizer, GlaxoSmithKline, Biogen Idec and Johnson &Johnson

  • Neurodegenerative research needs better cooperation, say GlobalData Neurodegenerative research needs better cooperation, say GlobalData

    Advancements in drug discovery for neurodegenerative diseases could be boosted by greater cooperation between pharma companies and small research programmes, says GlobalData. ... In recent weeks, pharma has proved its dedication to research for

  • GSK and Lilly invest in $100m global Dementia Discovery Fund GSK and Lilly invest in $100m global Dementia Discovery Fund

    GSK and Lilly invest in $100m global Dementia Discovery Fund. Fund announced at WHO conference by UK health secretary Jeremy Hunt. ... Pharma giants GlaxoSmithKline and Lilly have revealed their involvement in the new global $100m Dementia Discovery Fund.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • The world is our laboratory The world is our laboratory

    This year, through J&J Innovation, we will invest $10m into the UK government-led Global Dementia Discovery Fund, supporting innovative research into the area. ... This was set up in 2013 to identify innovative solutions for dementia care.

  • Pharma deals in March 2015 Pharma deals in March 2015

    This month saw GSK invest $25m, J&J $10m and the UK Government $22m into the Dementia Discovery fund, a joint initiative also including Lilly, Biogen and Pfizer to research treatments

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Forecasting in Forgotten Markets

    To help address a lack of investment in novel dementia science a new £100M Dementia Discovery Fund ( ) was launched towards the end of last year. ... Managed by SV Life Sciences the fund is focused primarily on Phase I and II research and aims to help

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics